Genzyme has patented a method for detecting anti-drug antibodies in human body fluids. The method involves saturating free drug with excess ADA, forming drug/ADA complexes, and reducing interference in drug assays by dissociating the complexes using polyethylene glycol and an acidic solution. GlobalData’s report on Genzyme gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Premium Insights Genzyme Corp - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Genzyme, was a key innovation area identified from patents. Genzyme's grant share as of February 2024 was 61%. Grant share is based on the ratio of number of grants to total number of patents.

Method for reducing interference in drug assay due to antibodies